Beraprost sodium is a synthetic analogue of prostacyclin primarily indicated for the treatment of pulmonary hypertension. By acting as a potent vasodilator and inhibitor of platelet aggregation, this compound… Read more

![Chemical structure of Methyl 4-((1R,2R,3aS,8bS)-2-hydroxy-1-((3S,E)-3-hydroxy-4-methyloct-1-en-6-yn-1-yl)-2,3,3a,8b-tetrahydro-1H-cyclopenta[b]benzofuran-5-yl)butanoate](/_next/image?url=https%3A%2F%2Fassets.splendidlab.com%2F943544-75-0-Methyl-4-1R2R3aS8bS-2-hydroxy-1-3SE-3-hydroxy-4-methyloct-1-en-6-yn-1-yl-233a8b-tetrahydro-1H-cyclopentabbenzofuran-5-ylbutanoate.png&w=3840&q=75)

Beraprost sodium is a synthetic analogue of prostacyclin primarily indicated for the treatment of pulmonary hypertension. By acting as a potent vasodilator and inhibitor of platelet aggregation, this compound helps manage vascular resistance in patients. Laboratories involved in pharmaceutical research and quality control rely on comprehensive sets of reference standards to ensure the consistency and efficacy of this therapy. The collection below includes pharmaceutical reference standards, including non-pharmacopeial impurities, specific stereoisomers, and stable isotope-labelled compounds. These materials are essential for rigorous impurity profiling, method validation, and stability testing. By utilizing these characterized reference materials, analytical chemists can accurately identify degradation products, quantify related substances, and maintain compliance with regulatory standards throughout the lifecycle of beraprost sodium formulations.